About Werewolf Therapeutics, Inc.
https://werewolftx.comWerewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
CEO
Daniel J. Hicklin
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:6.68M
Value:$3.9M
MPM ASSET MANAGEMENT LLC
Shares:4.31M
Value:$2.52M
BIOIMPACT CAPITAL LLC
Shares:2.41M
Value:$1.41M
Summary
Showing Top 3 of 68
About Werewolf Therapeutics, Inc.
https://werewolftx.comWerewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $15.73M ▼ | $-16.37M ▲ | 0% | $-0.36 ▲ | $-15.32M ▲ |
| Q2-2025 | $0 | $17.14M ▼ | $-17.98M ▲ | 0% | $-0.4 | $-16.27M ▲ |
| Q1-2025 | $0 | $17.57M ▼ | $-18.09M ▲ | 0% | $-0.4 ▲ | $-16.4M ▲ |
| Q4-2024 | $0 | $20.35M ▲ | $-20.4M ▼ | 0% | $-0.46 ▼ | $-18.69M ▼ |
| Q3-2024 | $0 | $17.12M | $-16.67M | 0% | $-0.38 | $-14.97M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $65.71M ▼ | $79.63M ▼ | $50.01M ▼ | $29.61M ▼ |
| Q2-2025 | $77.6M ▼ | $92.57M ▼ | $51.1M ▲ | $41.46M ▼ |
| Q1-2025 | $92.04M ▼ | $107.24M ▼ | $49.93M ▼ | $57.31M ▼ |
| Q4-2024 | $111M ▼ | $126.93M ▼ | $53.54M ▲ | $73.39M ▼ |
| Q3-2024 | $122.83M | $140.04M | $50.66M | $89.38M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-16.37M ▲ | $-15.16M ▲ | $0 | $3.27M ▲ | $-11.88M ▲ | $-15.16M ▲ |
| Q2-2025 | $-17.98M ▲ | $-15.16M ▲ | $0 | $388K ▲ | $-14.78M ▲ | $-15.16M ▲ |
| Q1-2025 | $-18.09M ▲ | $-18.95M ▼ | $0 ▲ | $0 ▼ | $-18.95M ▼ | $-18.95M ▼ |
| Q4-2024 | $-20.4M ▼ | $-14.25M ▼ | $-123K ▼ | $2.55M ▲ | $-11.83M ▲ | $-14.38M ▼ |
| Q3-2024 | $-16.67M | $-12.46M | $-3K | $-6K | $-12.47M | $-12.46M |
CEO
Daniel J. Hicklin
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:6.68M
Value:$3.9M
MPM ASSET MANAGEMENT LLC
Shares:4.31M
Value:$2.52M
BIOIMPACT CAPITAL LLC
Shares:2.41M
Value:$1.41M
Summary
Showing Top 3 of 68